Literature DB >> 26225841

Enhanced nitric oxide bioavailability in coronary arteries prevents the onset of heart failure in rats with myocardial infarction.

Gisele K Couto1, Luiz Roberto G Britto1, José G Mill2, Luciana V Rossoni3.   

Abstract

AIM: The endothelium, mainly via nitric oxide (NO) release, adjusts the coronary flow. Cardiac function is closely linked to blood flow; thus, we tested the hypothesis that NO modulation in coronary arteries could be differentially adjusted after myocardial infarction (MI) in the presence or absence of heart failure (HF). METHODS AND
RESULTS: Four weeks after coronary occlusion, the infarcted rats were subdivided into rats without (MI) or with HF signs according to haemodynamic parameters. The septal coronary arteries were subsequently used to perform functional and molecular experiments. Acetylcholine (ACh)-induced relaxation was decreased in the coronary arteries following HF, whereas it was enhanced in the arteries of the MI compared with those of SHAM-operated (SO) rats. The relaxation induced by the NO donor was similar among the groups. NO production, which was evaluated by 4,5-diaminofluorescein diacetate, was reduced in the coronary arteries of the HF group and increased in the arteries with MI after ACh-induced stimulation. HF coronary arteries exhibited oxidative stress, which was evaluated via ethidium bromide-positive nuclei, whereas it was decreased in MI. To evaluate the mechanisms involved in the enhanced ACh-induced relaxation in the arteries following MI, certain septal coronary arteries were pre-incubated with L-NAME (a nonselective NO synthase (NOS) inhibitor), 7-NI (a selective neuronal NOS (nNOS) inhibitor) or LY294002 (a PI3-kinase inhibitor). L-NAME and LY294002 reduced ACh-induced relaxation in the MI and SO rats; however, these effects were greater in the MI arteries. 7-NI reduced only the ACh-relaxation in MI. In addition, the eNOS, nNOS, Akt, and superoxide dismutase isoform protein expressions were greater in the coronary arteries of the MI than in those of the SO groups.
CONCLUSION: Our data suggested that endothelial function was closely related to cardiac function after coronary occlusion. The coronary arteries from the HF rats exhibited reduced NO bioavailability, whereas the MI rats exhibited increased NO bioavailability because of increased eNOS/nNOS/PI3-kinase/Akt pathway and a reduction in ROS generation. These results suggest that enhanced NO modulation can prevent the onset of HF.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Coronary artery; Endothelium; Heart failure; Myocardial infarction; Nitric oxide; Ventricular performance

Mesh:

Substances:

Year:  2015        PMID: 26225841     DOI: 10.1016/j.yjmcc.2015.07.017

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  13 in total

1.  Mechanism of the switch from NO to H2O2 in endothelium-dependent vasodilation in diabetes.

Authors:  Cody Juguilon; Zhiyuan Wang; Yang Wang; Molly Enrick; Anurag Jamaiyar; Yanyong Xu; James Gadd; Chwen-Lih W Chen; Autumn Pu; Chris Kolz; Vahagn Ohanyan; Yeong-Renn Chen; James Hardwick; Yanqiao Zhang; William M Chilian; Liya Yin
Journal:  Basic Res Cardiol       Date:  2022-01-13       Impact factor: 12.416

Review 2.  Metabolic Biomarkers in Heart Failure.

Authors:  Chonyang L Albert; W H Wilson Tang
Journal:  Heart Fail Clin       Date:  2018-01       Impact factor: 3.179

Review 3.  Altered Nitric Oxide System in Cardiovascular and Renal Diseases.

Authors:  JongUn Lee; Eun Hui Bae; Seong Kwon Ma; Soo Wan Kim
Journal:  Chonnam Med J       Date:  2016-05-20

4.  N-acetylcysteine attenuates myocardial dysfunction and postischemic injury by restoring caveolin-3/eNOS signaling in diabetic rats.

Authors:  Wating Su; Yuan Zhang; Qiongxia Zhang; Jinjin Xu; Liying Zhan; Qiqi Zhu; Qingquan Lian; Huimin Liu; Zhong-Yuan Xia; Zhengyuan Xia; Shaoqing Lei
Journal:  Cardiovasc Diabetol       Date:  2016-10-12       Impact factor: 9.951

5.  Protective effect of N-acetylcysteine activated carbon release microcapsule on myocardial ischemia-reperfusion injury in rats.

Authors:  Zhaobin Cai; Tingting Shi; Rangxiao Zhuang; Hongying Fang; Xiaojie Jiang; Yidan Shao; Hongping Zhou
Journal:  Exp Ther Med       Date:  2017-12-18       Impact factor: 2.447

6.  Cardioprotective Action of Ginkgo biloba Extract against Sustained β-Adrenergic Stimulation Occurs via Activation of M2/NO Pathway.

Authors:  Thássio R R Mesquita; Itamar C G de Jesus; Jucilene F Dos Santos; Grace K M de Almeida; Carla M L de Vasconcelos; Silvia Guatimosim; Fabrício N Macedo; Robervan V Dos Santos; José E R de Menezes-Filho; Rodrigo Miguel-Dos-Santos; Paulo T D Matos; Sérgio Scalzo; Valter J Santana-Filho; Ricardo L C Albuquerque-Júnior; Rose N Pereira-Filho; Sandra Lauton-Santos
Journal:  Front Pharmacol       Date:  2017-05-11       Impact factor: 5.810

Review 7.  Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety.

Authors:  Abdullah Shaito; Duong Thi Bich Thuan; Hoa Thi Phu; Thi Hieu Dung Nguyen; Hiba Hasan; Sarah Halabi; Samar Abdelhady; Gheyath K Nasrallah; Ali H Eid; Gianfranco Pintus
Journal:  Front Pharmacol       Date:  2020-04-07       Impact factor: 5.810

8.  Selective inhibition of PKCβ2 improves Caveolin-3/eNOS signaling and attenuates lipopolysaccharide-induced injury by inhibiting autophagy in H9C2 cardiomyocytes.

Authors:  Zhou Yang; Wating Su; Yuan Zhang; Lu Zhou; Zhong-Yuan Xia; Shaoqing Lei
Journal:  J Mol Histol       Date:  2021-06-08       Impact factor: 2.611

Review 9.  An Update on Hydrogen Sulfide and Nitric Oxide Interactions in the Cardiovascular System.

Authors:  Dan Wu; Qingxun Hu; Deqiu Zhu
Journal:  Oxid Med Cell Longev       Date:  2018-09-09       Impact factor: 6.543

10.  Induction of caveolin-3/eNOS complex by nitroxyl (HNO) ameliorates diabetic cardiomyopathy.

Authors:  Hai-Jian Sun; Si-Ping Xiong; Zhi-Yuan Wu; Lei Cao; Meng-Yuan Zhu; Philip K Moore; Jin-Song Bian
Journal:  Redox Biol       Date:  2020-03-05       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.